Levels of the Stat4 Alpha and Stat4 Beta Isoforms in PBMCs From Patients With Crohn's Disease and Ulcerative Colitis

Inclusion Criteria

• •Children with a new diagnosis of Crohn's Disease and whose physician has not yet initiated corticosteroid treatment (10 Subjects):
• •Clinical diagnosis within the previous 21 days
• •Above age 7 and younger than age 18
• •Signed informed consent statement and assent statement.
• •Children with a new diagnosis of Ulcerative Colitis and whose physician has not yet initiated corticosteroid treatment (10 Subjects):
• •Clinical diagnosis within the previous 21 days
• •Above age 7 and younger than age 18
• •Signed informed consent statement and assent statement.
• •Children with Crohn's Disease whose physician has initiated Infliximab treatment for the first time (10 Subjects):
• •Clinical diagnosis of Crohn's Disease
• •Above age 7 and younger that age 18
• •Signed informed consent statement and assent statement.
• •Children with Ulcerative Colitis whose physician has initiated Infliximab treatment for the first time (10 Subjects):
• •Clinical diagnosis of Ulcerative Colitis
• •Above age 7 and younger than age 18
• •Signed informed consent statement and assent statement.
• •Healthy Controls (10 Subjects):
• •Above age 7 and younger than age 18
• •otherwise healthy, with no intercurrent illness as determined by a member of the study team using the eligibility checklist
• •controls will be gender and age (± 2 years) matched to the patient groups described above
• •Signed informed consent statement and assent statement